The veterinary laboratory will publish on January 19, after the stock market, its turnover for the 2021 financial year. The opportunity to come back to the forecasts of a firm of analysts on this file.
Virbac will publish its annual sales on January 19, the expectations of an analyst firm | Photo credits: Virbac
2021 has been a banner year for Virbac. The group specializing in the research, production and marketing of veterinary drugs, which will reveal its annual turnover on January 19, raised its annual objectives four times, before finally aiming for sales growth of between 16 and 18%. The analyst firm Midcap Partners is counting on a turnover of more than 1 billion euros.
The veterinary laboratory also forecasts a ratio of operating profit excluding depreciation to turnover of around 16%. More optimistic, the firm is betting on a slightly higher ratio, up to 16.7%.
8% growth in 2022
” Whether the 2022 financial year will face the high comparison basis of 2021 “, specifies the office of analysts, ” Virbac should continue to evolve in a market with more sustained growth than before the crisis “. They add table “ in 2022 on a turnover growth of 8% and a current operating margin (…) at 16% “.
Midcap Partners recommends keeping the Virbac share. The firm is aiming for a target price of 414 euros, 5% higher than the current price level.
THE